secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001193125-24-213726
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus appoints Julie Eastland to Board of Directors, effective Sept 3, 2024
------------------------------------------------------------------------------

- Board size increased to ten directors; Eastland is a Class I director and Audit Committee member.
- Eastland qualifies as independent under Nasdaq rules; compensation includes $60K/yr cash plus prorated equity grant valued at $266,666.67.
- She brings biotech and finance experience, most recently CEO of Harpoon Therapeutics until its acquisition by Merck in March 2024.
- No arrangements or family relationships with existing directors or officers; no disclosable transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312524213726/0001193125-24-213726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312524213726/d886086d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-213726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer